Dupilumab is a fully human monoclonal antibody belonging to the immunoglobulin G4 (IgG4) subclass that targets the interleukin-4 receptor alpha (IL-4Rα), effectively inhibiting the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are key mediators of type 2 inflammatory pathways, which are involved in the pathogenesis of atopic and allergic conditions. Dupilumab blocks the shared IL-4Rα component of type I (IL-4Rα/γC) and type II (IL-4Rα/IL-13Rα1) receptor complexes, thereby reducing type 2 helper T cell (Th2)-driven immune responses.
In both clinical and research settings, dupilumab is utilized to manage moderate to severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Its inhibition of IL-4 and IL-13 signaling results in reduced gene expression linked to inflammation, decreased Th2 cell activity, and limited activation of inflammatory cells such as mast cells and macrophages. Dupilumab’s efficacy in downregulating inflammatory pathways has made it a valuable therapeutic for eosinophilic esophagitis and other type 2 immunity-related diseases.
Due to its mechanism of action, dupilumab serves as a biomarker-relevant therapeutic in immunological research exploring cytokine-driven inflammation. Monitoring its levels and immunogenicity through therapeutic drug monitoring (TDM) and anti-drug antibody assays helps ensure optimal patient response, dose adjustment, and early detection of potential immune resistance.
This product is manufactured in Turkey by Matriks Biotek.